.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Covington
Daiichi Sankyo
Harvard Business School
Fuji
Novartis
Cipla
Medtronic
Julphar
AstraZeneca

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,596,750

« Back to Dashboard

Which drugs does patent 6,596,750 protect, and when does it expire?


Patent 6,596,750 protects JADENU and EXJADE and is included in two NDAs. There have been zero Paragraph IV challenges on Jadenu and

This patent has forty-six patent family members in thirty-four countries.

Summary for Patent: 6,596,750

Title: Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
Abstract:The use is described of 3,5-diphenyl-1,2,4-triazoles of the formula I ##STR1## in which R.sub.1 -R.sub.5 are as defined in the description. The compounds have useful pharmaceutical properties and are particularly active as iron chelators. They can be used for the treatment of iron overload in warm-blooded animals.
Inventor(s): Lattmann; Rene (Binningen, CH), Acklin; Pierre (Basel, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:10/252,899
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
JADENU
deferasirox
TABLET;ORAL206910-001Mar 30, 2015RXYesNo6,596,750► SubscribeY METHOD OF TREATING CHRONIC IRON OVERLOAD
Novartis Pharms Corp
JADENU
deferasirox
TABLET;ORAL206910-002Mar 30, 2015RXYesNo6,596,750► SubscribeY METHOD OF TREATING CHRONIC IRON OVERLOAD
Novartis Pharms Corp
JADENU
deferasirox
TABLET;ORAL206910-003Mar 30, 2015RXYesYes6,596,750► SubscribeY METHOD OF TREATING CHRONIC IRON OVERLOAD
Novartis
EXJADE
deferasirox
TABLET, FOR SUSPENSION;ORAL021882-001Nov 2, 2005ABRXYesNo6,596,750► SubscribeY METHOD OF TREATING CHRONIC IRON OVERLOAD
Novartis
EXJADE
deferasirox
TABLET, FOR SUSPENSION;ORAL021882-002Nov 2, 2005ABRXYesNo6,596,750► SubscribeY METHOD OF TREATING CHRONIC IRON OVERLOAD
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,596,750

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland1593/96Jun 25, 1996

Non-Orange Book Patents for Patent: 6,596,750

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,465,504 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators► Subscribe
6,723,742 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,596,750

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia718037► Subscribe
Bulgaria64248► Subscribe
Bulgaria103003► Subscribe
Brazil9709973► Subscribe
Canada2255951► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
Novartis
Express Scripts
UBS
Fuji
Federal Trade Commission
Cipla
Medtronic
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot